All In Biotech

Drug Trial Radar · NCT03100916

This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 690517 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Within Dose Groups) and Effect of Food on the Bioavailability of BI 690517 (Openlabel, Randomised, Two-way Cross-over)

Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

May 5, 2017

Primary completion

Nov 24, 2017

Study completion Nov 24, 2017

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Apr 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the trial is to investigate the safety and tolerability of BI 690517 in healthy male subjects following oral administration of multiple rising doses over 14 days (MRD part). Secondary objectives for the MRD part are the exploration of PK (Pharmacokinetic(s)), including dose proportionality, as well as investigation of linearity and PD (Pharmacodynamic(s)) of BI 690517 after multiple dosing. For the FE (food effect) part, the secondary objective is to investigate the relative bioavailability of BI 690517 under fasted conditions (Reference, R) compared to BI 690517 (single dose) after a high fat high caloric breakfast (Test, T).

Conditions

  • Healthy

Interventions

  • BI 690517Drug

    once daily

  • PlaceboDrug

    once daily

  • BI 690517 (Reference)Drug

    Fasting

  • BI 690517Drug

    Non- fasting

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [N (%)] of subjects with drug-related Adverse EventsTime frame: Day 30

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRS Clinical Research Services Mannheim GmbH

    Mannheim, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.